# BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy

> **NCT06769555** · NA · WITHDRAWN · sponsor: **Institute of Hematology & Blood Diseases Hospital, China**

## Conditions studied

- AL Amyloidosis

## Interventions

- **DRUG:** CM-336 BCMA/CD3 bispecific antibody

## Key facts

- **NCT ID:** NCT06769555
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-01-01
- **Primary completion:** 2026-08-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study protocol was withdrawn because, after modifications, the study transitioned from an Investigator-Initiated Trial (IIT) to an Investigational New Drug (IND) clinical trial. This change necessitated a multi-center approach.
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06769555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06769555, "BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06769555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*